ODYSSEY FH and patient unmet needs | Professor Raul Santos
Less than 1% of people with familial hypercholesterolaemia (FH), the commonest genetic disorder in the world are diagnosed. As FH patients have significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) their consequent risk of cardiovascular death is greatly increased. Therefore, the results of the ODYSSEY trial, which showed that treatment with a PCSK9 inhibitor, alirocumab reduced LDL-C by 50% on top of earlier reductions with high dose statins, is very impressive, Professor Raul Santos said. To find out more visit www.pcsk9forum.org.
Less than 1% of people with familial hypercholesterolaemia (FH), the commonest genetic disorder in the world are diagnosed. As FH patients have significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) their consequent risk of cardiovascular death is greatly increased. Therefore, the results of the ODYSSEY trial, which showed that treatment with a PCSK9 inhibitor, alirocumab reduced LDL-C by 50% on top of earlier reductions with high dose statins, is very impressive, Professor Raul Santos said. To find out more visit www.pcsk9forum.org.